Safety of proteasome inhibitor drugs for the treatment of multiple myeloma post-marketing: a pharmacovigilance investigation based on the FDA adverse event reporting system

Yu et al. (Mon,) studied this question.

www.synapsesocial.com/papers/68e5bc3fb6db6435875547a7 — DOI: https://doi.org/10.1080/14740338.2024.2393275

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports· 2001 · 1,695 citations
2. Multiple myeloma· 2011 · 13 citations
3. NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022· 2022 · 209 citations
4. Proteasome inhibitors: structure and function· 2017 · 160 citations
5. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study· 2015 · 842 citations